A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis

Summary Idiopathic recurrent pericarditis (IRP) impairs quality of life. Although its precise etiology is not certain, it is believed to be immunologically mediated. Its optimal treatments are unknown. Initial therapy is with non-steroidal anti-inflammatory drugs and colchicine. Steroids, which are...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiology cases 2011-10, Vol.4 (2), p.e93-e97
Main Authors: Scott, Ian C., MBChB, MRCP, MSc, Hajela, Vijay, MBBS, FRCP, Hawkins, Philip N., PhD, FRCP, FRCPath, Lachmann, Helen J., MD, FRCP
Format: Article
Language:English
Subjects:
Cardiovascular
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4023-7cdd64d716f9921e8b5c32d2473f3784a5ae684332c9082d201e4b950e34d1623
cites cdi_FETCH-LOGICAL-c4023-7cdd64d716f9921e8b5c32d2473f3784a5ae684332c9082d201e4b950e34d1623
container_end_page e97
container_issue 2
container_start_page e93
container_title Journal of cardiology cases
container_volume 4
creator Scott, Ian C., MBChB, MRCP, MSc
Hajela, Vijay, MBBS, FRCP
Hawkins, Philip N., PhD, FRCP, FRCPath
Lachmann, Helen J., MD, FRCP
description Summary Idiopathic recurrent pericarditis (IRP) impairs quality of life. Although its precise etiology is not certain, it is believed to be immunologically mediated. Its optimal treatments are unknown. Initial therapy is with non-steroidal anti-inflammatory drugs and colchicine. Steroids, which are often used, however may promote recurrences. European guidelines advocate azathioprine or cyclophosphamide in refractory cases despite limited evidence. We report two adults with IRP successfully treated with the interleukin-1 antagonist, anakinra. We combine this experience with the first systematic literature review of immunosuppression in IRP. A total of 8 papers were included in the review, which alongside our patients described 18 cases. The best treatments comprised anakinra and intravenous immunoglobulin, with respective remission rates of 100% and 67%. Cyclophosphamide and azathioprine were less efficacious. The unprovoked inflammatory episodes in our patients alongside their prompt response to anakinra indicate that in some instances IRP may represent an autoinflammatory condition. We suggest that in IRP refractory to initial treatment, anakinra should be considered as a potential therapy. Clinical trials are required to confirm its benefits in IRP.
doi_str_mv 10.1016/j.jccase.2011.07.003
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6265095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1878540911000533</els_id><sourcerecordid>2155164222</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4023-7cdd64d716f9921e8b5c32d2473f3784a5ae684332c9082d201e4b950e34d1623</originalsourceid><addsrcrecordid>eNpVkV1rFTEQhoMottT-A5FcenO2-dyPG6EUPwoFL9TrkJPM2mx3kzWz23L-vVlPrTUEMjAz70zeh5C3nFWc8fpiqAbnLEIlGOcVayrG5Atyytum3WnFupfP4hNyjjiwciRXrW5fkxPJtFSi0adkvaSbDkXIAZDa6CkecIHJLsHRMSyQ7bJmoBnuAzzQ1Jcaexditn-KwzStMeE6zxkQQ4o0lOtDmu1yWxQyuDVniAudywRnsw9LwDfkVW9HhPPH94z8-PTx-9WX3c3Xz9dXlzc7p5iQu8Z5Xyvf8LrvOsGh3WsnhReqkb1sWmW1hbpVUgrXsbYkGAe17zQDqTyvhTwjH46687qfwLuyR7ajmXOYbD6YZIP5PxPDrfmZ7k0tas06XQTePwrk9GsFXMwU0ME42ghpRSO41rxWQmyz1LHU5YSYoX8aw5nZoJnBHKGZDZphjSlEStu75ys-Nf1F9O8PUIwqDLJxY4jFyvEODoBDWnMsHhpuUBhmvm3cN-ycF-JaSvkbzfisUQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2155164222</pqid></control><display><type>article</type><title>A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><source>Open Access: PubMed Central</source><source>ScienceDirect Freedom Collection</source><creator>Scott, Ian C., MBChB, MRCP, MSc ; Hajela, Vijay, MBBS, FRCP ; Hawkins, Philip N., PhD, FRCP, FRCPath ; Lachmann, Helen J., MD, FRCP</creator><creatorcontrib>Scott, Ian C., MBChB, MRCP, MSc ; Hajela, Vijay, MBBS, FRCP ; Hawkins, Philip N., PhD, FRCP, FRCPath ; Lachmann, Helen J., MD, FRCP</creatorcontrib><description>Summary Idiopathic recurrent pericarditis (IRP) impairs quality of life. Although its precise etiology is not certain, it is believed to be immunologically mediated. Its optimal treatments are unknown. Initial therapy is with non-steroidal anti-inflammatory drugs and colchicine. Steroids, which are often used, however may promote recurrences. European guidelines advocate azathioprine or cyclophosphamide in refractory cases despite limited evidence. We report two adults with IRP successfully treated with the interleukin-1 antagonist, anakinra. We combine this experience with the first systematic literature review of immunosuppression in IRP. A total of 8 papers were included in the review, which alongside our patients described 18 cases. The best treatments comprised anakinra and intravenous immunoglobulin, with respective remission rates of 100% and 67%. Cyclophosphamide and azathioprine were less efficacious. The unprovoked inflammatory episodes in our patients alongside their prompt response to anakinra indicate that in some instances IRP may represent an autoinflammatory condition. We suggest that in IRP refractory to initial treatment, anakinra should be considered as a potential therapy. Clinical trials are required to confirm its benefits in IRP.</description><identifier>ISSN: 1878-5409</identifier><identifier>EISSN: 1878-5409</identifier><identifier>DOI: 10.1016/j.jccase.2011.07.003</identifier><identifier>PMID: 30534275</identifier><language>eng</language><publisher>Japan: Japanese College of Cardiology</publisher><subject>Cardiovascular</subject><ispartof>Journal of cardiology cases, 2011-10, Vol.4 (2), p.e93-e97</ispartof><rights>Japanese College of Cardiology</rights><rights>2011 Japanese College of Cardiology. Published by Elsevier Ltd. 2011 Japanese College of Cardiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4023-7cdd64d716f9921e8b5c32d2473f3784a5ae684332c9082d201e4b950e34d1623</citedby><cites>FETCH-LOGICAL-c4023-7cdd64d716f9921e8b5c32d2473f3784a5ae684332c9082d201e4b950e34d1623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265095/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265095/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30534275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, Ian C., MBChB, MRCP, MSc</creatorcontrib><creatorcontrib>Hajela, Vijay, MBBS, FRCP</creatorcontrib><creatorcontrib>Hawkins, Philip N., PhD, FRCP, FRCPath</creatorcontrib><creatorcontrib>Lachmann, Helen J., MD, FRCP</creatorcontrib><title>A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis</title><title>Journal of cardiology cases</title><addtitle>J Cardiol Cases</addtitle><description>Summary Idiopathic recurrent pericarditis (IRP) impairs quality of life. Although its precise etiology is not certain, it is believed to be immunologically mediated. Its optimal treatments are unknown. Initial therapy is with non-steroidal anti-inflammatory drugs and colchicine. Steroids, which are often used, however may promote recurrences. European guidelines advocate azathioprine or cyclophosphamide in refractory cases despite limited evidence. We report two adults with IRP successfully treated with the interleukin-1 antagonist, anakinra. We combine this experience with the first systematic literature review of immunosuppression in IRP. A total of 8 papers were included in the review, which alongside our patients described 18 cases. The best treatments comprised anakinra and intravenous immunoglobulin, with respective remission rates of 100% and 67%. Cyclophosphamide and azathioprine were less efficacious. The unprovoked inflammatory episodes in our patients alongside their prompt response to anakinra indicate that in some instances IRP may represent an autoinflammatory condition. We suggest that in IRP refractory to initial treatment, anakinra should be considered as a potential therapy. Clinical trials are required to confirm its benefits in IRP.</description><subject>Cardiovascular</subject><issn>1878-5409</issn><issn>1878-5409</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNpVkV1rFTEQhoMottT-A5FcenO2-dyPG6EUPwoFL9TrkJPM2mx3kzWz23L-vVlPrTUEMjAz70zeh5C3nFWc8fpiqAbnLEIlGOcVayrG5Atyytum3WnFupfP4hNyjjiwciRXrW5fkxPJtFSi0adkvaSbDkXIAZDa6CkecIHJLsHRMSyQ7bJmoBnuAzzQ1Jcaexditn-KwzStMeE6zxkQQ4o0lOtDmu1yWxQyuDVniAudywRnsw9LwDfkVW9HhPPH94z8-PTx-9WX3c3Xz9dXlzc7p5iQu8Z5Xyvf8LrvOsGh3WsnhReqkb1sWmW1hbpVUgrXsbYkGAe17zQDqTyvhTwjH46687qfwLuyR7ajmXOYbD6YZIP5PxPDrfmZ7k0tas06XQTePwrk9GsFXMwU0ME42ghpRSO41rxWQmyz1LHU5YSYoX8aw5nZoJnBHKGZDZphjSlEStu75ys-Nf1F9O8PUIwqDLJxY4jFyvEODoBDWnMsHhpuUBhmvm3cN-ycF-JaSvkbzfisUQ</recordid><startdate>201110</startdate><enddate>201110</enddate><creator>Scott, Ian C., MBChB, MRCP, MSc</creator><creator>Hajela, Vijay, MBBS, FRCP</creator><creator>Hawkins, Philip N., PhD, FRCP, FRCPath</creator><creator>Lachmann, Helen J., MD, FRCP</creator><general>Japanese College of Cardiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201110</creationdate><title>A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis</title><author>Scott, Ian C., MBChB, MRCP, MSc ; Hajela, Vijay, MBBS, FRCP ; Hawkins, Philip N., PhD, FRCP, FRCPath ; Lachmann, Helen J., MD, FRCP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4023-7cdd64d716f9921e8b5c32d2473f3784a5ae684332c9082d201e4b950e34d1623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Cardiovascular</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, Ian C., MBChB, MRCP, MSc</creatorcontrib><creatorcontrib>Hajela, Vijay, MBBS, FRCP</creatorcontrib><creatorcontrib>Hawkins, Philip N., PhD, FRCP, FRCPath</creatorcontrib><creatorcontrib>Lachmann, Helen J., MD, FRCP</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cardiology cases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, Ian C., MBChB, MRCP, MSc</au><au>Hajela, Vijay, MBBS, FRCP</au><au>Hawkins, Philip N., PhD, FRCP, FRCPath</au><au>Lachmann, Helen J., MD, FRCP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis</atitle><jtitle>Journal of cardiology cases</jtitle><addtitle>J Cardiol Cases</addtitle><date>2011-10</date><risdate>2011</risdate><volume>4</volume><issue>2</issue><spage>e93</spage><epage>e97</epage><pages>e93-e97</pages><issn>1878-5409</issn><eissn>1878-5409</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Summary Idiopathic recurrent pericarditis (IRP) impairs quality of life. Although its precise etiology is not certain, it is believed to be immunologically mediated. Its optimal treatments are unknown. Initial therapy is with non-steroidal anti-inflammatory drugs and colchicine. Steroids, which are often used, however may promote recurrences. European guidelines advocate azathioprine or cyclophosphamide in refractory cases despite limited evidence. We report two adults with IRP successfully treated with the interleukin-1 antagonist, anakinra. We combine this experience with the first systematic literature review of immunosuppression in IRP. A total of 8 papers were included in the review, which alongside our patients described 18 cases. The best treatments comprised anakinra and intravenous immunoglobulin, with respective remission rates of 100% and 67%. Cyclophosphamide and azathioprine were less efficacious. The unprovoked inflammatory episodes in our patients alongside their prompt response to anakinra indicate that in some instances IRP may represent an autoinflammatory condition. We suggest that in IRP refractory to initial treatment, anakinra should be considered as a potential therapy. Clinical trials are required to confirm its benefits in IRP.</abstract><cop>Japan</cop><pub>Japanese College of Cardiology</pub><pmid>30534275</pmid><doi>10.1016/j.jccase.2011.07.003</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1878-5409
ispartof Journal of cardiology cases, 2011-10, Vol.4 (2), p.e93-e97
issn 1878-5409
1878-5409
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6265095
source BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS; Open Access: PubMed Central; ScienceDirect Freedom Collection
subjects Cardiovascular
title A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T06%3A33%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20series%20and%20systematic%20literature%20review%20of%20anakinra%20and%20immunosuppression%20in%20idiopathic%20recurrent%20pericarditis&rft.jtitle=Journal%20of%20cardiology%20cases&rft.au=Scott,%20Ian%20C.,%20MBChB,%20MRCP,%20MSc&rft.date=2011-10&rft.volume=4&rft.issue=2&rft.spage=e93&rft.epage=e97&rft.pages=e93-e97&rft.issn=1878-5409&rft.eissn=1878-5409&rft_id=info:doi/10.1016/j.jccase.2011.07.003&rft_dat=%3Cproquest_pubme%3E2155164222%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4023-7cdd64d716f9921e8b5c32d2473f3784a5ae684332c9082d201e4b950e34d1623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2155164222&rft_id=info:pmid/30534275&rfr_iscdi=true